Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002004636 | SCV002230397 | uncertain significance | Hyper-IgM syndrome type 5 | 2021-09-15 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamine with histidine at codon 133 of the UNG protein (p.Gln133His). The glutamine residue is highly conserved and there is a small physicochemical difference between glutamine and histidine. This variant is present in population databases (rs576044400, ExAC 0.02%). This variant has not been reported in the literature in individuals affected with UNG-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004043926 | SCV003710860 | uncertain significance | not specified | 2021-08-10 | criteria provided, single submitter | clinical testing | The c.399A>C (p.Q133H) alteration is located in exon 3 (coding exon 3) of the UNG gene. This alteration results from a A to C substitution at nucleotide position 399, causing the glutamine (Q) at amino acid position 133 to be replaced by a histidine (H). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |